Sexual health problems in French cancer survivors two years after diagnosis – the national VICAN survey
Ali Ben Charif
(1)
,
Anne Deborah Bouhnik
(2)
,
Blandine Courbiere
(3, 4)
,
Rey Dominique
(1, 2)
,
Marie Préau
(1, 5)
,
Marc Karim Bendiane
(6)
,
Patrick Peretti Watel
(1)
,
Julien Mancini
(7, 1, 2)
1
SESSTIM - U912 INSERM - Aix Marseille Univ - IRD -
Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
2 ORS PACA
3 IMBE - Institut méditerranéen de biodiversité et d'écologie marine et continentale
4 Service de Gynécologie et Obstétrique [Marseille]
5 GRePS - Groupe de Recherche en Psychologie Sociale
6 Epidémiologie et Sciences Sociales Appliquées à l'Innovation Médicale
7 APHM - Assistance Publique - Hôpitaux de Marseille
2 ORS PACA
3 IMBE - Institut méditerranéen de biodiversité et d'écologie marine et continentale
4 Service de Gynécologie et Obstétrique [Marseille]
5 GRePS - Groupe de Recherche en Psychologie Sociale
6 Epidémiologie et Sciences Sociales Appliquées à l'Innovation Médicale
7 APHM - Assistance Publique - Hôpitaux de Marseille
Anne Deborah Bouhnik
- Fonction : Auteur
- PersonId : 21073
- IdHAL : anne-deborah-bouhnik
- ORCID : 0000-0002-5418-4592
- IdRef : 144192012
Blandine Courbiere
- Fonction : Auteur
- PersonId : 174040
- IdHAL : blandine-courbiere
- ORCID : 0000-0002-1847-4509
- IdRef : 094988129
Marie Préau
- Fonction : Auteur
- PersonId : 171105
- IdHAL : preau-marie
- ORCID : 0000-0002-6239-1671
- IdRef : 084340525
Marc Karim Bendiane
- Fonction : Auteur
- PersonId : 172807
- IdHAL : marc-karim-bendiane
- ORCID : 0000-0003-4329-8807
- IdRef : 248778587
Patrick Peretti Watel
- Fonction : Auteur
- PersonId : 1177992
- ORCID : 0000-0002-4675-0478
- IdRef : 052601161
Julien Mancini
- Fonction : Auteur
- PersonId : 21170
- IdHAL : julien-mancini
- ORCID : 0000-0001-9500-8598
- IdRef : 109373278
Résumé
BACKGROUND
Antiretroviral preexposure prophylaxis has been shown to reduce the risk of human
immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting
results have been reported among studies, probably due to challenges of
adherence to a daily regimen.
METHODS
We conducted a double-blind, randomized trial of antiretroviral therapy for preexposure
HIV-1 prophylaxis among men who have unprotected anal sex with men.
Participants were randomly assigned to take a combination of tenofovir disoproxil
fumarate (TDF) and emtricitabine (FTC) or placebo before and after sexual
activity. All participants received risk-reduction counseling and condoms and were
regularly tested for HIV-1 and HIV-2 and other sexually transmitted infections.
RESULTS
Of the 414 participants who underwent randomization, 400 who did not have HIV
infection were enrolled (199 in the TDF-FTC group and 201 in the placebo group).
All participants were followed for a median of 9.3 months (interquartile range, 4.9 to
20.6). A total of 16 HIV-1 infections occurred during follow-up, 2 in the TDF-FTC
group (incidence, 0.91 per 100 person-years) and 14 in the placebo group (incidence,
6.60 per 100 person-years), a relative reduction in the TDF-FTC group of 86% (95%
confidence interval, 40 to 98; P = 0.002). Participants took a median of 15 pills of
TDF-FTC or placebo per month (P = 0.57). The rates of serious adverse events were
similar in the two study groups. In the TDF-FTC group, as compared with the
placebo group, there were higher rates of gastrointestinal adverse events (14% vs. 5%,
P = 0.002) and renal adverse events (18% vs. 10%, P = 0.03).
CONCLUSIONS
The use of TDF-FTC before and after sexual activity provided protection against
HIV-1 infection in men who have sex with men. The treatment was associated with
increased rates of gastrointestinal and renal adverse events. (Funded by the National
Agency of Research on AIDS and Viral Hepatitis [ANRS] and others;
ClinicalTrials.gov number, NCT01473472.)
Domaines
PsychologieFormat du dépôt | Notice |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
Sexual health problems in French cancer survivors two years after diagnosis – the national VICAN survey
|
Résumé |
en
BACKGROUND
Antiretroviral preexposure prophylaxis has been shown to reduce the risk of human
immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting
results have been reported among studies, probably due to challenges of
adherence to a daily regimen.
METHODS
We conducted a double-blind, randomized trial of antiretroviral therapy for preexposure
HIV-1 prophylaxis among men who have unprotected anal sex with men.
Participants were randomly assigned to take a combination of tenofovir disoproxil
fumarate (TDF) and emtricitabine (FTC) or placebo before and after sexual
activity. All participants received risk-reduction counseling and condoms and were
regularly tested for HIV-1 and HIV-2 and other sexually transmitted infections.
RESULTS
Of the 414 participants who underwent randomization, 400 who did not have HIV
infection were enrolled (199 in the TDF-FTC group and 201 in the placebo group).
All participants were followed for a median of 9.3 months (interquartile range, 4.9 to
20.6). A total of 16 HIV-1 infections occurred during follow-up, 2 in the TDF-FTC
group (incidence, 0.91 per 100 person-years) and 14 in the placebo group (incidence,
6.60 per 100 person-years), a relative reduction in the TDF-FTC group of 86% (95%
confidence interval, 40 to 98; P = 0.002). Participants took a median of 15 pills of
TDF-FTC or placebo per month (P = 0.57). The rates of serious adverse events were
similar in the two study groups. In the TDF-FTC group, as compared with the
placebo group, there were higher rates of gastrointestinal adverse events (14% vs. 5%,
P = 0.002) and renal adverse events (18% vs. 10%, P = 0.03).
CONCLUSIONS
The use of TDF-FTC before and after sexual activity provided protection against
HIV-1 infection in men who have sex with men. The treatment was associated with
increased rates of gastrointestinal and renal adverse events. (Funded by the National
Agency of Research on AIDS and Viral Hepatitis [ANRS] and others;
ClinicalTrials.gov number, NCT01473472.)
|
Auteur(s) |
Ali Ben Charif
1
, Anne Deborah Bouhnik
2
, Blandine Courbiere
3, 4
, Rey Dominique
1, 2
, Marie Préau
1, 5
, Marc Karim Bendiane
6
, Patrick Peretti Watel
1
, Julien Mancini
7, 1, 2
1
SESSTIM - U912 INSERM - Aix Marseille Univ - IRD -
Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
( 540465 )
- Faculté de Médecine - Site Timone - 27 Bd Jean Moulin 13385 – Marseille Cedex 05
- France
2
ORS PACA
( 300140 )
-
- France
3
IMBE -
Institut méditerranéen de biodiversité et d'écologie marine et continentale
( 188653 )
- Aix Marseille Université, Campus Etoile, Faculté St-Jérôme case 421 Av. . escadrille Normandie-Niemen 13397 MARSEILLE CEDEX 20
- France
4
Service de Gynécologie et Obstétrique [Marseille]
( 203638 )
- 147, boulevard Baille 13005 Marseille
- France
5
GRePS -
Groupe de Recherche en Psychologie Sociale
( 49955 )
- Université Lyon 2 - Institut de Psychologie 5 avenue Pierre Mendès-France - 69676 BRON cedex
- France
6
Epidémiologie et Sciences Sociales Appliquées à l'Innovation Médicale
( 2821 )
- Institut Paoli-Calmettes 232, Boulevard Sainte Marguerite 13273 Marseille Cedex 09
- France
7
APHM -
Assistance Publique - Hôpitaux de Marseille
( 300073 )
- Direction générale AP-HM
80, rue Brochier
13 354 Marseille Cedex 5
- France
|
Date de publication |
2015
|
Langue du document |
Anglais
|
Nom de la revue |
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Domaine(s) |
|
Mots-clés |
en
Social psychology, Health psychology
|
DOI | 10.1007/s11764-015-0506-3 |
Loading...